Equities analysts expect Endocyte, Inc. (NASDAQ:ECYT) to report earnings of ($0.16) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Endocyte’s earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.15). Endocyte reported earnings of ($0.26) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 38.5%. The firm is scheduled to announce its next quarterly earnings results on Friday, March 9th.
On average, analysts expect that Endocyte will report full year earnings of ($1.24) per share for the current year, with EPS estimates ranging from ($1.25) to ($1.23). For the next year, analysts expect that the business will post earnings of ($0.91) per share, with EPS estimates ranging from ($1.02) to ($0.79). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Endocyte.
Endocyte (NASDAQ:ECYT) last posted its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.20). The business had revenue of $0.03 million during the quarter. Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. Endocyte’s revenue was up .0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.21) earnings per share.
ECYT has been the topic of several recent analyst reports. Zacks Investment Research lowered Endocyte from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Wedbush raised Endocyte from a “neutral” rating to an “outperform” rating and increased their target price for the company from $2.00 to $7.00 in a report on Tuesday, October 3rd. ValuEngine raised Endocyte from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Finally, Cowen and Company reissued a “hold” rating on shares of Endocyte in a report on Monday, October 2nd.
In related news, insider Philip S. Low acquired 5,600 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was bought at an average price of $4.84 per share, for a total transaction of $27,104.00. Following the completion of the purchase, the insider now directly owns 283,005 shares of the company’s stock, valued at approximately $1,369,744.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 14.86% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ECYT. Dimensional Fund Advisors LP boosted its stake in Endocyte by 34.1% in the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 25,003 shares in the last quarter. Spark Investment Management LLC acquired a new position in Endocyte in the second quarter valued at $177,000. LMR Partners LLP acquired a new position in Endocyte in the second quarter valued at $196,000. Ameriprise Financial Inc. boosted its stake in Endocyte by 26.7% in the first quarter. Ameriprise Financial Inc. now owns 133,270 shares of the biopharmaceutical company’s stock valued at $343,000 after acquiring an additional 28,110 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Endocyte by 4.7% in the first quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock valued at $369,000 after acquiring an additional 6,469 shares in the last quarter. Institutional investors own 25.47% of the company’s stock.
Endocyte (NASDAQ ECYT) traded down $0.73 during trading hours on Tuesday, reaching $4.60. The company had a trading volume of 1,283,500 shares, compared to its average volume of 1,217,522. Endocyte has a 52-week low of $1.17 and a 52-week high of $6.55.
COPYRIGHT VIOLATION WARNING: This story was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.thestockobserver.com/2017/11/14/0-16-eps-expected-for-endocyte-inc-ecyt-this-quarter.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.